Article

Levofloxacin 1.5% earns FDA approval

Minneapolis, MN-The new fluoroquinolone, levofloxacin 1.5% ophthalmic solution (IQUIX, Santen), has received FDA approval to be marketed for the treatment of bacterial corneal ulcer. The approval brings with it a milestone as the first current-generation fluoroquinolone with an indication for use in the management of that sight-threatening condition, explained Richard L. Lindstrom, MD.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
© 2024 MJH Life Sciences

All rights reserved.